Northway Biotech is a leading global CDMO specializing in gene therapy and protein-based biologics. With 20+ years of expertise and 210+ successful programs, we provide an integrated path from cell line development to cGMP Drug Substance and Drug Product manufacturing. Our cGMP facilities in Vilnius and Waltham support rapid scaling across all stages, from early development to commercial phases. We specialize in pDNA, AV, AAV, and lentiviral programs, complemented by comprehensive early and late-phase viral clearance studies. Currently expanding our strategic capabilities, Northway Biotech will launch ADC and cell therapy manufacturing in Q3 2026.